In 2008, the WHO published the updated classification of myeloid neoplasms; one of the major changes in this review is the incorporation of NPM1 and CEBPA mutations such as entities within the group of AML with recurrent genetic abnormalities. This evidence concerns the gene NPM1 and acute myeloid leukemia.